Eledon Pharmaceuticals Inc expected to post a loss of 65 cents a share - Earnings Preview

Eledon Pharmaceuticals

10/11/2021 03:01

* Eledon Pharmaceuticals Inc  ELDN.OQ   ELDN.O  is expected
to show no change in quarterly revenue when it reports 
results on November 11. 
​* Refinitiv's mean analyst estimate for Eledon Pharmaceuticals
Inc is for a loss of 65 cents per share. For the same quarter
last year, the company reported a loss of $5.51 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Eledon
Pharmaceuticals Inc is $29​, about 82.6% above​ its last closing
price of $5.04. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2021  -0.58       -0.57      -0.50     Beat    11.9
 Mar. 31 2021  -0.34       -0.32      -0.57     Missed  -78.1
 Dec. 31 2020  -0.31       -1.39      -2.12     Missed  -52​
 Sep. 30 2020  -1.82       -1.75      -5.51     Missed  -215.5
 ​​Jun.        -2.70       -2.97      -2.16     Beat    27.3
 30 2020                                                
 Mar. 31 2020  -2.86       -2.88      -3.42     Missed  -18.7​
 Dec. 31 2019  -4.66       -4.68      -3.24     Beat    30.8
 Sep. 30 2019  -7.38       -7.29      -3.96     Beat    45.7
 This summary was machine generated November 10 at 03:01 GMT. 
All figures in US dollars  unless otherwise stated